Feature | March 28, 2013

Women with Dense Breasts Welcome Additional Screening

Four different categories of breast density: fatty (top left), scattered fibroglandular (top right), heterogeneously dense (bottom left) and extremely dense (bottom right).

This image shows fatty breast density.

This image shows scattered fibroglandular breast density.

This image shows heterogeneously dense breast density.

This image shows extremely dense breast density.

December 11, 2012 — A survey of women undergoing routine screening mammography found that many of them would be interested in pursuing additional screening tests if notified they had dense breast tissue, despite the possibility of false positives, invasive procedures, and out-of-pocket costs, according to a clniical study presented at the annual meeting of the Radiological Society of North America (RSNA).

"Our study highlights the need for patient education regarding breast density," said Jafi Lipson, M.D., assistant professor of radiology at Stanford University School of Medicine in Stanford, Calif.

Recent studies have found that dense breast tissue is a strong independent risk factor for breast cancer. Breasts are composed of fat and fibroglandular tissue. Dense breast fibroglandular tissue appears white on a mammogram. Abnormalities and tumors also appear white on mammograms, causing them to be difficult to spot in dense breasts until the cancers are much larger and possibly in advanced stages.

"We hope this study raises awareness that dense breast tissue is a risk factor for breast cancer and that alternative technologies, including automated whole-breast ultrasound and contrast-enhanced mammography, are available to aid in screening women with dense breasts," said Haatal B. Dave, M.D., M.S., resident physician at Yale University School of Medicine in New Haven, Conn.

For the study, Lipson and Dave surveyed 105 women undergoing routine screening mammography at an outpatient radiology clinic. The women were asked if they knew their breast density and were informed about the association between higher breast density and increased risk of breast cancer. Women were then asked a set of questions about whether or not they would be interested in additional screening tests, such as automated whole-breast ultrasound or contrast-enhanced mammography, if they found out that they had dense breasts.

Of the 105 women surveyed, 76 percent were unaware of their breast density. Forty-two percent of the women had dense or extremely dense breast tissue. A majority of the surveyed women showed interest in the additional screening, despite the chance of increased false positives, invasive biopsy procedures and potential out-of-pocket expense.

Dave noted that educating the general public about the association between breast density and breast cancer risk is important, but that supplemental screenings are a matter of some debate in the medical and political realms. She added that many states do not require insurance companies to cover the cost for supplemental tests due to the lack of evidence of their mortality benefit.

Currently five states, including Connecticut, New York, Texas, California and Virginia, have passed bills that require radiologists to inform women of their breast density if they are found to have dense breast tissue. In 2011, a similar bill was introduced on a national level, and more than 10 other states have legislation pending.

Related Content

News | Nuclear Imaging | June 24, 2016
Developers of a new portable molecular imaging system debuted their creation at the 2016 Annual Meeting of the Society...
PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016
Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
VASH collimator, DOE, molecular breast imaging, SNMMI 2016

Adding this variable angle slant hole collimator to an existing breast molecular imaging system allows the system to get six times better contrast of cancer lesions in the breast, providing the same or better image quality while also potentially reducing the radiation dose to the patient by half. Technologies developed at DOE’s Jefferson Lab for the variable angle slant hole collimator are included in two filings to the U.S. Patent and Trademark Office. Image courtesy of DOE’s Jefferson Lab.

News | Breast Imaging | June 21, 2016
Preliminary tests have demonstrated that a new device may enable up to six times better contrast of tumors in the...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
Positron emission tomography (PET) with three different radiotracers can now measure amyloid plaques, tau tangles and...
Hologic, KLAS Research, Tomosynthesis 2016, Genius 3-D Mammography, Selenia Dimensions
News | Mammography | June 15, 2016
Hologic announced that the company received top marks from U.S. mammography providers in a new independent report from...
hypertrophic cardiomyopathy, HCM, strain echocardiography, risk assessment, ASE 2016
News | Cardiovascular Ultrasound | June 13, 2016
After following a large sub-set of patients, researchers found that by using strain echocardiography they could...
Overlay Init